BPC-157 and TB-500 Tendon Healing: What a New Rat Study Reports
A paper published 23 July 2026 in Joint Diseases and Related Surgery set out to compare BPC-157, synthetic thymosin beta-4 (TB-500), and the two peptides administered together in a rat Achilles tendon repair model. Two findings stand out for anyone following the animal literature on these compounds. First, the authors report that only the TB-500 arm reached statistical significance on the main biomechanical measure. Second, they report that giving both together produced no clear improvement over either one alone.
That second result is especially relevant because these compounds are often discussed as a package deal in tendon and soft-tissue contexts, as if pairing them should automatically be additive. Few controlled models actually test that assumption with single-agent groups plus a combination group. This one did.
What they did
Listed under the Orthopaedics and Traumatology Clinic at Bagcilar Training and Research Hospital in Istanbul, the team used 32 male Sprague-Dawley rats, 12 weeks old, about 330 g each. Every rat received a standardized Achilles tendon transection followed by surgical repair.
After surgery, the animals were randomized into four groups, eight per group:
- control
- BPC-157, 10 µg/kg/day
- TB-500, 60 µg/kg/day
- BPC-157 and TB-500 together
Both peptides were delivered intraperitoneally for four weeks. At week four, the tendons were collected and assigned either to biomechanical testing or to histological work.
For a study of this size, the assessment menu was broad. Mechanics were summarized as maximum load to failure. Tissue evaluation used haematoxylin and eosin plus Masson trichrome, Alcian blue, and Sirius red staining. They scored the sections with Bonar and Movin systems, semi-quantitative scales where lower totals point to less degenerative change. Collagen types I and III were checked by immunohistochemistry and semi-quantified using H-score.
The authors describe the project as exploratory.
What they report
Biomechanics
Maximum load to failure increased in both peptide-only groups relative to control, but the authors say the difference reached statistical significance only for TB-500 (p < 0.05). BPC-157 moved upward numerically without clearing the significance bar.
Histology scores
Bonar totals were significantly lower for TB-500 versus controls (p = 0.016). Movin totals were significantly lower in the TB-500 group and also in the combined group (p = 0.017 and p = 0.040). The authors read these lower totals as better overall tendon structure, improved collagen alignment, and less degenerative change.
For BPC-157, they again report scores trending lower, but not significantly on the totals.
Collagen “layout” versus collagen “amount”
A more subtle part of the paper sits in the collagen findings. With Sirius red birefringence, the authors observed greater organization of type I collagen and shifts in the distribution of type III collagen in the peptide-treated groups, most noticeably under TB-500. Their interpretation is that the repair matrix is moving toward a more mature pattern.
Immunohistochemistry, though, did not mirror that in a simple one-to-one way. They report no significant between-group differences in type I collagen expression, while type III collagen expression did differ significantly, which they note lines up with the histochemical readouts.
These two techniques are not asking the same question. Birefringence is about fiber arrangement, immunohistochemistry is about relative presence. So organization can change even when expression levels do not, and the authors present both results without pretending they are the same thing.
The combination did not outperform either peptide alone
Their plainest conclusion on performance is that giving BPC-157 and TB-500 together did not add a measurable advantage beyond either peptide alone.
They do offer a possible reason, framed as a hypothesis rather than a proven mechanism: the two peptides might funnel into overlapping downstream pathways, so stacking them provides no extra gain. They also state that this would need direct experimental testing.
For researchers designing protocols around these two compounds, this is arguably the most directly useful result in the paper, and it cuts against a common expectation.
What the study does not show
The authors’ constraints are straightforward and worth keeping in view. This is a rat model, not human data. The follow-up is four weeks, so it captures early repair rather than long-term remodeling. Each peptide was tested at only one dose, with no dose-ranging component.
Their closing position is that both peptides justify more work as possible adjuncts in tendon repair, but only with dose optimization and longer-duration studies.
A related note appears in a 2019 Cell Tissue Res review on BPC-157, which emphasized that most evidence so far comes from small rodent studies, that efficacy in humans is still unconfirmed, and that relatively few research teams have produced deep, sustained work on the peptide across the past two decades.
Where this sits next to earlier literature
For BPC-157 in tendon tissue, a frequently cited mechanistic base comes from a 2011 Journal of Applied Physiology study using rat Achilles tendon explants and cultured tendon fibroblasts. That group reported faster fibroblast outgrowth from explants and improved survival under hydrogen peroxide stress, without a direct effect on proliferation in an MTT assay. They also reported dose-dependent increases in migration and spreading, alongside increased phosphorylation of FAK and paxillin, and tied the effect to the FAK-paxillin pathway.
Thymosin beta-4 is typically described differently. A 2010 review by Philp and Kleinman at the NIH described it as a major actin-sequestering molecule and summarized animal findings that include down-regulating inflammatory chemokines and cytokines, supporting cell migration, angiogenesis, survival, and aspects of stem cell maturation.
Against that backdrop, the 2026 result, where TB-500 is the arm that reaches biomechanical significance, lands in the same general neighborhood as the earlier repair-associated profile described for thymosin beta-4. The new paper does not claim to explain why, and a summary should not pretend it does. For readers trying to compare mechanisms, an overview of how BPC-157 and TB-500 differ can serve as a useful companion to the primary report.
References
- Bicer O, Adanir O, Guleryuz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. https://pubmed.ncbi.nlm.nih.gov/42542926/ · https://doi.org/10.52312/jdrs.2026.2951
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. https://pubmed.ncbi.nlm.nih.gov/21030672/
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. https://pubmed.ncbi.nlm.nih.gov/30915550/
- Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81-86. https://pubmed.ncbi.nlm.nih.gov/20536453/
The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.
